Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market – Industry Trends and Forecast to 2029

Postmenopausal Vaginal Atrophy (PVA) Drugs Market Analysis and Size

The global postmenopausal vaginal atrophy (PVA) drugs market is expected to witness significant growth during the forecast period. The common symptoms associated with this condition include irritation, burning sensation, redness, and dyspareunia. Several branded and generic drugs are available in the market for the treatment of postmenopausal vaginal atrophy. The development of top non-estrogen-based drugs has also helped the market gain pace in the recent years. In addition to this, the enhancement of the healthcare reforms for meeting the requirements to treat vaginal atrophy is also a major factor boosting the development of the market.

Data Bridge Market Research analyses a growth rate in global postmenopausal vaginal atrophy (PVA) drugs market in the forecast period 2022-2029. The expected CAGR of global postmenopausal vaginal atrophy (PVA) drugs market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 2 billion in 2021, and it would grow upto USD 3.57 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Postmenopausal Vaginal Atrophy (PVA) Drugs Market Scope and Segmentation

Market Definition

Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market Dynamics

Drivers

• Prevalence of Postmenopausal Vaginal Atrophy

The increasing incidence of postmenopausal vaginal atrophy boosts the demand for treatment methods. The most prevalent symptom is vaginal dryness which affects 60% of women in the postmenopausal period. These symptoms can generally lead to sexual dysfunction and subsequently to reduced quality of life.

• Growing Healthcare Plans

Numerous established healthcare infrastructures, as well as the increased frequency of disease and the occurrence of significant manufacturers, are the primary factors contributing to the market share. For instance, The Affordable Care Act has increased the number of insured women and has been a boosting factor in the treatment-seeking behavior of people with this condition. Furthermore, this law provides many U.S. citizens with better health security by putting in place comprehensive health insurance reforms that have reduced healthcare costs and expanded coverage. Consequently, the introduction of beneficial healthcare plans in the US will prompt more women to seek treatment, thereby helping in the growth of this market during the forecast period.

Opportunities

• Increased Awareness of the Disease

The rising awareness among the population about this kind of disease results in the market's growth. The growing awareness about the benefits of postmenopausal vaginal atrophy drugs encourages people to opt for this treatment. Furthermore, in developed countries such as the US, women can openly discuss their symptoms with their physician, which creates awareness and helps in early diagnosis, thus encouraging this market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of postmenopausal vaginal atrophy drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in highly advanced countries create much opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

• Lack of Awareness about the infection

The lack of awareness about these infections could curb the growth of the global postmenopausal vaginal atrophy drugs market over a forecast period. Not much attention about the infection leads to improper treatment thus restraining the market growth.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth. Several antifungal, antiviral, antibacterial drugs are facing an increasing hike and thus is hampering the market growth.

This global postmenopausal vaginal atrophy (PVA) drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global postmenopausal vaginal atrophy (PVA) drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market    

The COVID-19 pandemic has hindered the development, production, and supply of drugs and other healthcare products and affected many companies' growth of healthcare businesses worldwide. However, in the post-pandmeic era, the market is projected to grow because of an increase in R&D initiatives for exact diagnosis. Numerous government and non-government bodies, including the European Institute of Women's Health (EIWH) and the World Health Organization, have launched multiple public awareness campaigns about women's health.Thus, COVID-19 left a major imapact on the global postmenopausal vaginal atrophy (PVA) drugs market.

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market Scope

The global postmenopausal vaginal atrophy (PVA) drugs market is segmented on the basis of drugs, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Topical Estrogen
• Oral Estrogen
• Others

Product

• Creams
• Pessaries
• Tablets
• Gels
• Solutions
• Inserts
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Postmenopausal Vaginal Atrophy (PVA) Drugs Market Regional Analysis/Insights

The global postmenopausal vaginal atrophy (PVA) drugs market is analyzed and market size insights and trends are provided by drugs, product, distribution channel and end-user as referenced above.

The major countries covered in the global postmenopausal vaginal atrophy (PVA) drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global postmenopausal vaginal atrophy (PVA) drugs market throughout the forecasted period because of the increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and increased occurrence of vaginal infection in women.

North America dominates the market because of the increasing initiatives taken by the pharmaceutical organizations to generate novel formulation and well-spread awareness of anti-infectives among end-users. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market Share Analysis

The global postmenopausal vaginal atrophy (PVA) drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related global postmenopausal vaginal atrophy (PVA) drugs market.

Key players operating in the global postmenopausal vaginal atrophy (PVA) drugs market include:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• AbbVie Inc. (Ireland)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Lupin (India)
• Perrigo Company plc (U.S.)
• Bionovo, Inc. (Saudi Arabia)
• TherapeuticsMD, Inc. (U.S.)
• Endoceutics, Inc (Canada)

SKU-55130